Blog
About

12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.

      Annals of Neurology

      Vesicular Monoamine Transport Proteins, Adult, Vesicular Biogenic Amine Transport Proteins, Tomography, Emission-Computed, metabolism, analogs & derivatives, Tetrabenazine, Rats, Presynaptic Terminals, radionuclide imaging, Parkinson Disease, Neuropeptides, Middle Aged, Membrane Transport Proteins, pharmacokinetics, Membrane Glycoproteins, Male, Humans, Female, Cerebral Cortex, Blood-Brain Barrier, Biological Transport, Biological Markers, Animals, Aging, Aged

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We present development and human application of a method for determining the regional cerebral density of the type 2 vesicular monoamine transporter (VMAT2) using positron emission tomography (PET) and [11C]dihydrotetrabenazine (DTBZ). Previous animal studies indicate striatal VMAT2 density is linearly related to the integrity of substantia nigra dopamine neurons and is not subject to drug- or lesion-compensatory regulation. In the present studies, kinetic compartmental modeling was employed to estimate blood-brain [11C]DTBZ transport (K1) and VMAT2 binding site density (tissue-to-plasma DTBZ distribution volume, DV) from the cerebral and plasma DTBZ time courses after intravenous tracer injection. In controls, we found reductions of putamen DTBZ DVwith advancing age, corresponding to losses of 0.77% per year in specific VMAT2 binding. Parkinson's disease (PD) patients had reduction in specific DTBZ DV in the putamen (-61%) and in the caudate nucleus (-43%). There was no overlap of lowest specific putamen DTBZ DV between individual elderly controls and PD patients. The present results indicate the suitability of [11C]DTBZ PET for objective quantification of nigrostriatal integrity, including evaluation of PD progression and its possible therapeutic modification.

          Related collections

          Author and article information

          Journal
          10.1002/ana.410400609
          9007092

          Comments

          Comment on this article